Exelixis Inc Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Exelixis Inc (EXEL) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-07.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2012-11-07
- Exelixis Inc incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2012-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Exelixis Inc incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2011-09-30 was 449.00K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month |
|---|---|---|
| 2012-09-30 | 0.00 shares 10-Q · filed 2012-11-07 | 0.00 shares 10-Q · filed 2012-11-07 |
| 2011-09-30 | 449.00K shares 10-Q · filed 2012-11-07 | 1.57M shares 10-Q · filed 2012-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |